{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:53:00Z","timestamp":1792011180402,"version":"4.4.0"},"reference-count":0,"publisher":"Harborside Press, LLC","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10]]},"abstract":"Background:<\/jats:bold> The incidence and survival of colorectal cancer (CRC) are increasing. There is an increasing number of long-term survivors, many of whom are elderly and have comorbidities. We conducted a population-based study in Hong Kong to assess the long-term cardiovascular disease (CVD) incidence associated with adjuvant fluoropyrimidine-based chemotherapy among CRC survivors. Patients and Methods:<\/jats:bold> Using the population-based electronic medical database of Hong Kong, we identified adults who were diagnosed with high-risk stage II\u2013III CRC and treated with radical surgery followed by adjuvant fluoropyrimidine-based chemotherapy between 2010 and 2019. We evaluated the cause-specific cumulative incidence of CVD (including ischemic heart disease, heart failure, cardiomyopathy, and stroke) using the flexible parametric competing risk modeling framework. The control group without a history of CVD was selected from among a noncancer random sample from primary care clinics in the same geographic area. Results:<\/jats:bold> We analyzed 1,037 treated patients with CRC and 5,078 noncancer controls. The adjusted cause-specific hazard ratio (HR) for CVD in the cancer cohort compared with the control group was 2.11 (95% CI, 1.39\u20133.20). The 1-, 5-, and 10-year cause-specific cumulative incidences were 2.0%, 4.5%, and 5.4% in the cancer cohort versus 1.2%, 3.0%, and 3.8% in the control group, respectively. Age at cancer diagnosis (HR per 5-year increase, 1.16; 95% CI, 1.08\u20131.24), male sex (HR, 1.40; 95% CI, 1.06\u20131.86), comorbidity (HR, 1.88; 95% CI, 1.36\u20132.61 for 1 comorbidity vs none, and HR, 6.61; 95% CI, 4.55\u20139.60 for \u22652 comorbidities vs none), diabetes (HR, 1.38; 95% CI, 1.04\u20131.84), hypertension (HR, 3.27; 95% CI, 2.39\u20134.50), and dyslipidemia\/hyperlipidemia (HR, 2.53; 95% CI, 1.68\u20133.81) were associated with incident CVD. Conclusions:<\/jats:bold> Exposure to adjuvant fluoropyrimidine-based chemotherapy was associated with an increased risk of CVD among survivors of high-risk stage II\u2013III CRC. Cardiovascular risk monitoring of this group throughout cancer survivorship is advisable.<\/jats:p>","DOI":"10.6004\/jnccn.2022.7042","type":"journal-article","created":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T19:09:55Z","timestamp":1665774595000},"page":"1125-1133.e10","source":"Crossref","is-referenced-by-count":15,"title":["Incident Cardiovascular Diseases Among Survivors of High-Risk Stage II\u2013III Colorectal Cancer: A Cluster-Wide Cohort Study"],"prefix":"10.6004","volume":"20","author":[{"given":"Shing Fung","family":"Lee","sequence":"first","affiliation":[{"name":"1Department of Clinical Oncology, Tuen Mun Hospital, New Territories West Cluster, Hospital Authority, Hong Kong, China;"},{"name":"2Department of Clinical Oncology, Queen Mary Hospital, Hong Kong West Cluster, Hospital Authority, Hong Kong, China;"},{"name":"3Department of Radiation Oncology, National University Cancer Institute, Singapore;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pui Lam","family":"Yip","sequence":"additional","affiliation":[{"name":"1Department of Clinical Oncology, Tuen Mun Hospital, New Territories West Cluster, Hospital Authority, Hong Kong, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balamurugan A.","family":"Vellayappan","sequence":"additional","affiliation":[{"name":"3Department of Radiation Oncology, National University Cancer Institute, Singapore;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng Ean","family":"Chee","sequence":"additional","affiliation":[{"name":"4Department of Haematology-Oncology, National University Cancer Institute, Singapore;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea Choung","family":"Wong","sequence":"additional","affiliation":[{"name":"3Department of Radiation Oncology, National University Cancer Institute, Singapore;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric Yuk-Fai","family":"Wan","sequence":"additional","affiliation":[{"name":"5Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China;"},{"name":"6Laboratory of Data Discovery for Health, Hong Kong Science and Technology Park, Sha Tin, Hong Kong, China;"},{"name":"7Department of Family Medicine and Primary Care, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther Wai-Yin","family":"Chan","sequence":"additional","affiliation":[{"name":"5Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China;"},{"name":"6Laboratory of Data Discovery for Health, Hong Kong Science and Technology Park, Sha Tin, Hong Kong, China;"},{"name":"8The University of Hong Kong Shenzhen Institute of Research and Innovation, Shenzhen, China;"},{"name":"9Department of Pharmacy, University of Hong Kong\u2013Shenzhen Hospital, Shenzhen, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chak-Fei","family":"Lee","sequence":"additional","affiliation":[{"name":"10Department of Pharmacy, Tuen Mun Hospital, New Territories West Cluster, Hospital Authority, Hong Kong, China;"},{"name":"11School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis Ann-Shing","family":"Lee","sequence":"additional","affiliation":[{"name":"1Department of Clinical Oncology, Tuen Mun Hospital, New Territories West Cluster, Hospital Authority, Hong Kong, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel Angel","family":"Luque-Fernandez","sequence":"additional","affiliation":[{"name":"12Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom;"},{"name":"13Inequalities in Cancer Outcomes Network, London School of Hygiene and Tropical Medicine, London, United Kingdom;"},{"name":"14Department of Non-Communicable Disease and Cancer Epidemiology, Instituto de Investigacion Biosanitaria de Granada, Granada, Spain;"},{"name":"15Cancer Registry of Granada, Andalusian School of Public Health, Granada, Spain; and"},{"name":"16Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Epidemiolog\u00eda y Salud P\u00fablica (CIBER of Epidemiology and Public Health, CIBERESP), Madrid, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/20\/10\/article-p1125.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/20\/10\/article-p1125.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T19:09:59Z","timestamp":1665774599000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/20\/10\/article-p1125.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":0,"journal-issue":{"issue":"10"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2022.7042","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10]]}}}